

Title (en)
NOVEL COMPOUNDS

Title (de)
NEUARTIGE VERBINDUNGEN

Title (fr)
NOUVEAUX COMPOSES

Publication
EP 0770135 A1 19970502 (EN)

Application
EP 95930435 A 19950728

Priority
• EP 9503036 W 19950728
• GB 9415379 A 19940729
• US 46829795 A 19950606

Abstract (en)
[origin: WO9604388A1] A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to at least one human immunoglobulin constant domain or fragment thereof.

IPC 1-7
C12N 15/62; C07K 14/54; C07K 16/00; C07K 19/00; A61K 38/19; A61K 39/395

IPC 8 full level
A61K 38/00 (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/08** (2006.01); **C07K 14/54** (2006.01); **C07K 16/00** (2006.01); **C07K 19/00** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12N 15/62** (2006.01); **C12P 21/02** (2006.01); **C12R 1/91** (2006.01)

CPC (source: EP)
A61P 37/00 (2017.12); **A61P 37/08** (2017.12); **C07K 14/5406** (2013.01); **C07K 16/00** (2013.01); **A61K 38/00** (2013.01); **C07K 2319/00** (2013.01)

Citation (search report)
See references of WO 9604388A1

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9604388 A1 19960215; AU 3382595 A 19960304; BR 9508469 A 19970916; CA 2196200 A1 19960215; CN 1117155 C 20030806; CN 1164872 A 19971112; CZ 25697 A3 19970917; EP 0770135 A1 19970502; HU T76369 A 19970828; JP H10503371 A 19980331; MX 9700764 A 19970531; NO 970374 D0 19970128; NO 970374 L 19970219; NZ 292124 A 19981028; PL 182665 B1 20020228; PL 318380 A1 19970609

DOCDB simple family (application)
EP 9503036 W 19950728; AU 3382595 A 19950728; BR 9508469 A 19950728; CA 2196200 A 19950728; CN 95195305 A 19950728; CZ 25697 A 19950728; EP 95930435 A 19950728; HU 9700260 A 19950728; JP 50619296 A 19950728; MX 9700764 A 19950728; NO 970374 A 19970128; NZ 29212495 A 19950728; PL 31838095 A 19950728